       Document 0231
 DOCN  M9620231
 TI    Protective immune responses induced by secretion of a chimeric soluble
       protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin
       vector candidate vaccine for human immunodeficiency virus type 1 in
       small animals.
 DT    9602
 AU    Honda M; Matsuo K; Nakasone T; Okamoto Y; Yoshizaki H; Kitamura K;
       Sugiura W; Watanabe K; Fukushima Y; Haga S; et al; AIDS Research Center,
       National Institute of Health, Tokyo, Japan.
 SO    Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10693-7. Unique Identifier :
       AIDSLINE MED/96068682
 AB    A recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG)
       vector-based vaccine that secretes the V3 principal neutralizing epitope
       of human immunodeficiency virus (HIV) could induce immune response to
       the epitope and prevent the viral infection. By using the Japanese
       consensus sequence of HIV-1, we successfully constructed chimeric
       protein secretion vectors by selecting an appropriate insertion site of
       a carrier protein and established the principal neutralizing determinant
       (PND)-peptide secretion system in BCG. The recombinant BCG
       (rBCG)-inoculated guinea pigs were initially screened by delayed-type
       hypersensitivity (DTH) skin reactions to the PND peptide, followed by
       passive transfer of the DTH by the systemic route. Further, immunization
       of mice with the rBCG resulted in induction of cytotoxic T lymphocytes.
       The guinea pig immune antisera showed elevated titers to the PND peptide
       and neutralized HIVMN, and administration of serum IgG from the
       vaccinated guinea pigs was effective in completely blocking the HIV
       infection in thymus/liver transplanted severe combined immunodeficiency
       (SCID)/hu or SCID/PBL mice. In addition, the immune serum IgG was shown
       to neutralize primary field isolates of HIV that match the neutralizing
       sequence motif by a peripheral blood mononuclear cell-based virus
       neutralization assay. The data support the idea that the
       antigen-secreting rBCG system can be used as a tool for development of
       HIV vaccines.
 DE    Amino Acid Sequence  Animal  Antibodies, Viral/BLOOD  AIDS
       Vaccines/*IMMUNOLOGY  Base Sequence  Enzyme-Linked Immunosorbent Assay
       Genetic Vectors  Guinea Pigs  Human  HIV Envelope Protein
       gp120/*IMMUNOLOGY  HIV Infections/*PREVENTION & CONTROL
       HIV-1/IMMUNOLOGY  Immunization, Passive  Mice  Mice, SCID  Middle Age
       Molecular Sequence Data  Mycobacterium bovis/GENETICS  Neutralization
       Tests  Peptide Fragments/*IMMUNOLOGY  Skin Tests  Support, Non-U.S.
       Gov't  T-Lymphocytes, Cytotoxic  Vaccines, Synthetic/*IMMUNOLOGY  Viral
       Proteins/SECRETION  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

